Search

Your search keyword '"Jastrzębski, Dariusz"' showing total 103 results
Start Over Author "Jastrzębski, Dariusz"
103 results on '"Jastrzębski, Dariusz"'

6. Expectations, symptoms, and quality of life before and after 1 year of Pirfenidone treatment in patients with idiopathic pulmonary fibrosis: A single‐arm, open‐label nonrandomized study

Author

Jastrzębski, Dariusz, primary, Kostorz‐Nosal, Sabina, additional, Galle, Dagmara, additional, Gałeczka‐Turkiewicz, Alicja, additional, Warzecha, Joanna, additional, Majewski, Sebastian, additional, Piotrowski, Wojciech J., additional, and Ziora, Dariusz, additional

Published
2023
Full Text
View/download PDF

7. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

Author

Majewski, Sebastian, Białas, Adam J., Buchczyk, Małgorzata, Gomółka, Paweł, Górska, Katarzyna, Jagielska-Len, Hanna, Jarzemska, Agnieszka, Jassem, Ewa, Jastrzębski, Dariusz, Kania, Aleksander, Koprowski, Marek, Krenke, Rafał, Kuś, Jan, Lewandowska, Katarzyna, Martusewicz-Boros, Magdalena M., Roszkowski-Śliż, Kazimierz, Siemińska, Alicja, Sładek, Krzysztof, Sobiecka, Małgorzata, Szewczyk, Karolina, Tomczak, Małgorzata, Tomkowski, Witold, Wiatr, Elżbieta, Ziora, Dariusz, Żołnowska, Beata, and Piotrowski, Wojciech J.

Published
2020
Full Text
View/download PDF

11. Guidelines of the Polish Respiratory Society on the Diagnosis and Treatment of Progressive Fibrosing Interstitial Lung Diseases Other than Idiopathic Pulmonary Fibrosis

Author

Piotrowski, Wojciech, primary, Martusewicz-Boros, Magdalena, additional, Białas, Adam, additional, Barczyk, Adam, additional, Batko, Bogdan, additional, Błasińska, Katarzyna, additional, Boros, Piotr, additional, Górska, Katarzyna, additional, Grzanka, Piotr, additional, Jassem, Ewa, additional, Jastrzębski, Dariusz, additional, Kaczyńska, Janina, additional, Kowal-Bielecka, Otylia, additional, Kucharz, Eugeniusz, additional, Kuś, Jan, additional, Kuźnar-Kamińska, Barbara, additional, Kwiatkowska, Brygida, additional, Langfort, Renata, additional, Lewandowska, Katarzyna, additional, Mackiewicz, Barbara, additional, Majewski, Sebastian, additional, Makowska, Joanna, additional, Miłkowska-Dymanowska, Joanna, additional, Puścińska, Elżbieta, additional, Siemińska, Alicja, additional, Sobiecka, Małgorzata, additional, Soroka-Dąda, Renata, additional, Szołkowska, Małgorzata, additional, Wiatr, Elżbieta, additional, Ziora, Dariusz, additional, and Śliwiński, Paweł, additional

Published
2022
Full Text
View/download PDF

12. A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study.

Author

Majewski, Sebastian, Białas, Adam J., Barczyk, Adam, Batura-Gabryel, Halina, Buchczyk, Małgorzata, Doboszyńska, Anna, Górska, Katarzyna, Grabowska-Skudlarz, Luiza, Jagielska-Len, Hanna, Jarzemska, Agnieszka, Jassem, Ewa, Jastrzębski, Dariusz, Kania, Aleksander, Koprowski, Marek, Krawczyk, Michał, Krenke, Rafał, Lewandowska, Katarzyna, Mackiewicz, Barbara, Martusewicz-Boros, Magdalena M., and Milanowski, Janusz

Subjects
IDIOPATHIC pulmonary fibrosis, DRUG side effects, PULMONARY function tests, SCIENTIFIC observation, ABDOMINAL pain
Abstract

Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe the safety and efficacy profiles of nintedanib in a large real-world cohort of Polish patients with IPF. This was a multicenter, retrospective, observational study of IPF patients treated with nintedanib between March 2018 and October 2021. Data collection included baseline clinical characteristics, results of pulmonary function tests (PFTs), and a six-minute walk test (6MWT). Longitudinal data on PFTs, 6MWT, adverse drug reactions (ADRs), and treatment persistence were also retrieved. A total of 501 patients (70% male) with a median age of 70.9 years (IQR 65–75.7) were included in this study. Patients were followed on treatment for a median of 15 months (7–25.5). The majority of patients (66.7%) were treated with the full recommended dose of nintedanib and 33.3% of patients were treated with a reduced dose of a drug. Intermittent dose reductions or drug interruptions were needed in 20% of patients. Over up to 3 years of follow-up, pulmonary function remained largely stable with the minority experiencing disease progression. The most frequent ADRs included diarrhea (45.3%), decreased appetite (29.9%), abdominal discomfort (29.5%), weight loss (32.1%), nausea (20.8%), fatigue (19.2%), increased liver aminotransferases (15.4%), and vomiting (8.2%). A total of 203 patients (40.5%) discontinued nintedanib treatment due to diverse reasons including ADRs (10.2%), death (11.6%), disease progression (4.6%), patient's request (6.6%), and neoplastic disease (2.2%). This real-world study of a large cohort of Polish patients with IPF demonstrates that nintedanib therapy is safe, and is associated with acceptable tolerance and disease stabilization. These data support the findings of previously conducted clinical trials and observational studies on the safety and efficacy profiles of nintedanib in IPF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Guidelines of the Polish Respiratory Society for Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis

Author

Piotrowski, Wojciech, primary, Bestry, Iwona, additional, Białas, Adam, additional, Boros, Piotr, additional, Grzanka, Piotr, additional, Jassem, Ewa, additional, Jastrzębski, Dariusz, additional, Klimczak, Dariusz, additional, Langfort, Renata, additional, Lewandowska, Katarzyna, additional, Majewski, Sebastian, additional, Martusewicz-Boros, Magdalena, additional, Oniszh, Karina, additional, Puścińska, Elżbieta, additional, Siemińska, Alicja, additional, Sobiecka, Małgorzata, additional, Szołkowska, Małgorzata, additional, Wiatr, Elżbieta, additional, Wilczyński, Gracjan, additional, Ziora, Dariusz, additional, and Kuś, Jan, additional

Published
2020
Full Text
View/download PDF

25. Clinical features and outcome of adult patients with pulmonary Langerhans cell histiocytosis

Author

Radzikowska, Elżbieta, primary, Wiatr, Elzbieta, additional, Błasińska-Przerwa, Katarzyna, additional, Jeśkiewicz, Maria, additional, Langfort, Reanta, additional, Maksymiuk, Beata, additional, Modrzewska, Katarzyna, additional, Bestry, Iwona, additional, Załęska, Monika, additional, Szopinski, Janusz, additional, Jerzemska, Agnieszka, additional, Ochman, Marek, additional, Naumnik, Wojciech, additional, Jastrzębski, Dariusz, additional, Piotrowski, Wojciech, additional, and Roszkowski-Śliż, Kazimierz, additional

Published
2019
Full Text
View/download PDF

28. Forced oscillation measurements in patients after lobectomy – A comparative analysis with IPF and COPD patients.

Author

Kostorz‐Nosal, Sabina, Jastrzębski, Dariusz, and Ziora, Dariusz

Subjects
*LOBECTOMY (Lung surgery), *IDIOPATHIC pulmonary fibrosis, *OBSTRUCTIVE lung diseases, *EXPIRATORY flow, *OSCILLATIONS, *THORACIC surgery
Abstract

Objectives: Forced oscillation technique (FOT) is becoming increasingly widespread measurement method used for assessment of lung function. In the present study, we attempted to assess FOT values in patients after lobectomy in comparison with IPF and COPD patients. Methods: Twenty‐two patients after lobectomy due to lung cancer stage I or II, 28 patients with idiopathic pulmonary fibrosis and 17 patients with chronic obstructive pulmonary disease were enrolled in the study. All patients performed spirometry (FEV1, FVC, FEV1/FVC, MEF50, MEF25, FEF25‐75, MIF50), plethysmography (Raw, TLC, RV, RV/TLC) and a test using the forced oscillation technique‐ resistance (R at 5Hz, 11Hz and 19Hz, inspiratory, expiratory and total), reactance (Xat 5Hz, 11Hz, inspiratory, expiratory and total), Fres and expiratory flow limitation (∆X). The ANOVA Kruskal‐Wallis test followed by a multiple comparison test were used to evaluate the differences in oscillatory parameters between‐groups. Results: Patients after lobectomy presented reduced X5, X11 and moderately increased R5, R11, R19, R5‐19, ∆X and Fres. Rinsp5 weresignificantly higher when compared with IPF patients (P = 0.001). In lobectomy patients R5, X5, X11, ∆X and Fres were significantly less affected when compared with patients with COPD (P < 0.05 for all values). R5‐19, which reflects small airways dysfunction, occurred to be similarly elevated as in COPD patients (0.5 vs 0.6 cmH2O/L/s).Abnormalities of reactance at 11Hz were observed more frequently than at 5Hz in all groups of patients. Conclusion: Patients after lobectomy due to lung cancer presented FOT abnormalities, which could be caused by lung parenchymal abnormalities following recent thoracic surgery. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

29. A functional assessment of patients two years after lung transplantation in Poland

Author

Jastrzębski, Dariusz T., Gumola, Anna, Wojarski, Jacek, Żegleń, Sławomir, Ochman, Marek, Czyżewski, Damian, Ziora, Dariusz, Zembala, Marian, and Kozielski, Jerzy

Subjects
Heart and Lung Failure, Transplantology, lung transplantation, lung function tests, dyspnea, respiratory tract diseases
Abstract

The aim of the study was to assess the long-term results of lung transplantation (LT) in Poland two years after the procedure.The study included patients who underwent LT between December 2004 and December 2009 in the Silesian Center for Heart Diseases in Zabrze. Various lung functions (forced vital capacity - FVC; forced expiratory volume in 1 second - FEV1), the quality of life (SF-36 questionnaire), the level of perceived dyspnea (Medical Research Council - MRC; basic dyspnea index - BDI), and the patient's mobility (the 6-minute walking test - 6MWT) were assessed before and approximately 24 months after LT. Among 35 patients who underwent LT, 20 patients were referred to our study (mean age: 46.6 ± 9.03 years).After LT, a statistically significant increase was observed in the distance achieved in the 6MWT (323.8 vs. 505.8 m), FVC (1.64 vs. 2.88 L), and FEV1 (1.37 vs. 2.09 L). An improvement in perceived dyspnea in MRC and BDI questionnaires was observed in patients with chronic obstructive pulmonary disease (COPD) after LT. The assessment of the quality of life, excluding perceived pain, showed the most significant improvement in the physical cumulative score (PCS; 25 vs. 45 points), especially in patients with idiopathic pulmonary fibrosis.Lung transplantation in Poland, in patients who live longer than 2 years after the procedure, significantly improves the mobility, lung function, perceived dyspnea, and the quality of life.Odległa ocena efektu transplantacji płuc (Badaniem objęto chorych, u których w okresie grudzień 2004 r. – grudzień 2009 r. (5 lat) wykonano zabieg LT w Śląskim Centrum Chorób Serca (SCCS) w Zabrzu. W trakcie kwalifikacji oceniono czynność płuc (FVC, FEVPo przeszczepie stwierdzono istotne statystycznie przyrosty: dystansu 6 MWT z 323,8 m do 505,8 m, FVC (1,64Transplantacja płuca w Polsce u chorych, którzy przeżyli 2 lata od zabiegu, jest procedurą w sposób istotny poprawiającą mobilność, czynność układu oddechowego, odczuwanie duszności oraz postrzeganie jakości życia.

Published
2014

37. Rehabilitacja Oddechowa Chorych na Raka Płuca

Author

Jastrzębski, Dariusz, primary, Ziora, Dariusz, additional, Hydzik, Grzegorz, additional, Pasko, Ewa, additional, Bartoszewicz, Agnieszka, additional, Kozielski, Jerzy, additional, and Nowicka, Jolanta, additional

Published
2012
Full Text
View/download PDF

50. Fatigue in patients with inactive sarcoidosis does not correlate with lung ventilation ability or walking distance. Pilot Study.

Author

Zieleźnik K, Jastrzębski D, and Ziora D

Subjects
Adult, Dyspnea, Female, Humans, Male, Middle Aged, Pilot Projects, Quality of Life, Respiratory Function Tests, Exercise Tolerance, Fatigue etiology, Sarcoidosis complications, Sarcoidosis physiopathology, Walking
Abstract

Introduction: Fatigue is one of many symptoms reported by patients with sarcoidosis. It is believed that fatigue may be the cause of exercise intolerance and reduced quality of life in patients with sarcoidosis. The purpose of the work was to present the frequency of fatigue prevalence in patients with sarcoidosis and to investigate the correlation between fatigue and the results of pulmonary function tests and walking distance., Material and Methods: A total of 74 patients with sarcoidosis in a stable phase of the disease, not treated in the past with glucocorticoids or immunosuppressive drugs, and without indications for treatment at the time of the study were examined. In all patients fatigue evaluation was carried out with the use of the Fatigue Assessment Scale questionnaire (FAS); dyspnoea was assessed with the use of the Medical Research Council scale (MRC). Body Mass Index (BMI), spirometry, and a 6-minute walk test were additionally performed. The control group included 30 healthy volunteers who completed the FAS., Results: In the examined group of patients fatigue was diagnosed in 36 patients (50%), and in 5 (6.94%) - strong fatigue was observed. The remaining 31 (43.06%) patients felt no fatigue. The average value of points obtained by FAS questionnaire in sarcoidosis patients was significantly higher than the respective value in the control group (p = 0.02). A significantly higher number of points by FAS questionnaire was observed in female patients with sarcoidosis (p = 0.04) in comparison to men. No significant statistical correlation between fatigue index FAS and BMI (r = 0.22, p = 0.11), FEV1 (r = -0.11, p = 0.3), FEV1% pred. (r = 0.01, p = 0.9), FVC (r = -0.03, p = 0.77), FEF25-75 (r = -0.23, p = 0.1) and the distance in the six-minute walk test (6MWT) (r = -0.01, p = 0.9) was observed. However, there was a weak negative correlation between the age of the patients and the FAS index (r = -0.29, p = 0.01)., Conclusions: Fatigue in patients with sarcoidosis does not correlate with the results of lung function tests or with walking distance in 6MWT.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results